Skip to main content

Table 2 Univariate analyses of prognostic factors for 3-year cancer-specific survival

From: The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis

 

Statistics

3-year CSS

N (%)

HR (95%CI), P value

Gender

 Male

244 (61.00%)

Ref

 Female

156 (39.00%),

1.27 (0.60, 2.72), 0.532

Age (year)

54.55 ± 12.81

1.01 (0.98, 1.04), 0.432

 < 65

298 (74.50%)

Ref

 ≥ 65

102 (25.50%)

1.20 (0.53, 2.74), 0.6637

T stage

 T1–2

21 (5.25%)

Ref

 T3–4

379 (94.75%)

1.35 (0.18, 9.97), 0.7669

N stage

 N0

182 (45.50%)

ref

 N1

140 (35.00%)

2.66 (0.66, 10.62) 0.1670

 N2

78 (19.50%)

15.55 (4.58, 52.82) < 0.0001

Differentiation

Moderate to high

350 (87.50%)

Ref

Poor

50 (12.50%)

2.05 (0.83, 5.08), 0.1209

PLNR

0.145 ± 0.23

27.97 (9.88, 79.19), < 0.0001

 < 0.145

286 (71.50%)

Ref

 ≥ 0.145

114 (28.50%)

7.56 (3.20, 17.88), < 0.0001

PNI

49.05 ± 5.51

0.93 (0.87, 1.00), 0.0403

PNI tertile

 T1

132 (33.00%)

Ref

 T2

134 (33.50%)

0.34 (0.12, 0.95), 0.0398

 T3

134 (33.50%)

0.54 (0.23, 1.30), 0.1686

NLR

3.21 ± 3.19

1.08 (1.00, 1.15), 0.0367

NLR tertile

 T1

133 (33.25%)

Ref

 T2

133 (33.25%)

0.87 (0.29, 2.58), 0.7990

 T3

134 (33.50%)

2.05 (0.83, 5.08), 0.1211

Number of ACT cycles

5.43 ± 3.17

0.82 (0.72, 0.93), 0.0022

 0

36 (9.00%)

Ref

 1–6

228 (57.00%)

0.28 (0.12, 0.67), 0.0044

 7–12

136 (34.00%)

0.21 (0.07, 0.61), 0.0042

CCRT

 Without

147 (36.75%)

Ref

 With

253 (63.25%)

1.09 (0.49, 2.43), 0.8296

  1. Abbreviations: PLNR Positive lymph nodes ratio, CA Carcinoma antigen, CEA Carcinoembryonic antigen, CCRT Concurrent chemoradiotherapy, ACT Adjuvant chemotherapy, PNI Prognostic nutritional index, NLR Neutrophil-lymphocyte ratio